| This Biotech's Next Move Could Reshape the Sector, With 4 Others in Motion |
|
| One health giant is quietly building momentum behind an experimental treatment with breakout potential. | Analysts are watching closely as the next trial update approaches, and short-term setups are tightening. Here's what traders are watching today, and 4 more stocks with fresh catalysts. |
|
| | | | Amgen | AMGN | | Price: $301.33 | Amgen is drawing new interest as it progresses with AMG 732, a first-in-class treatment targeting Thyroid Eye Disease (TED). The autoimmune disorder has limited options today, and this new therapy could significantly change the landscape. | The early Phase 1/2 trial uses a rigorous design with double masking and randomized assignment to ensure robust data. | Investors are watching technicals as closely as the science. | AMGN is consolidating around $300, and chart analysts see a 9.5% upside from current levels with low near-term risk. Institutional flow also appears to be picking up. | If results hit key safety or efficacy benchmarks, AMG 732 could become a pivotal asset in Amgen's pipeline. | In a market hungry for defensiveness with upside, this setup checks both boxes. |
|
| | Miss Nothing (Sponsored) | | | The secret to finding big moves that could end up like the ones below is knowing where to look: | Triller Group Inc (ILLR): From $.66 to $8.86 (+1,242%) | Quantum Computing Inc (QUBT): From $.35 to $4.69 (+1,240%) | Eco Wave Power (WAVE): From $1.01 to $12.39 (+1,126%) | The choice is yours: You can do nothing, and you'll end up on the sidelines for the next +1,200% move. Or you can take action… | Not long from now, Market Pulse Today will reveal its first alert of the quarter—a company with serious breakout potential. | The best part? | It's 100% free. | [Click Here to Get the Alert First] | You can make it happen or wonder "What happened?"
(By clicking the link above, you agree to receive emails from Market Pulse. You can opt out at any time. - Privacy Policy) |
|
| | Starbucks | SBUX | | Price: $92.78 | Starbucks shares jumped 4% in after-hours trading following a solid revenue beat and signs of life in China. | While global same-store sales fell for the sixth consecutive quarter, CEO Brian Niccol emphasized that the turnaround plan is ahead of schedule. | The company is doubling down on customer service with its "Green Apron Service" and investing $500 million in labor over the next year. | Crucially, licensed stores on college campuses and in North America showed better-than-expected comps. Niccol pointed to improved partner engagement and a rebound in customer transactions, especially from non-loyalty members. | A new Rewards program and food innovation pipeline are on deck for 2026. | While investors may not yet see a complete comeback in the numbers, operational momentum suggests the worst may be over. |
|
| | Visa | V | | Price: $350.92 | Visa's Q2 numbers came in strong, with EPS of $2.98 and $10.17 billion in revenue, beating expectations. However, the company's decision to maintain low-double-digit guidance sent shares down after the bell. | Analysts saw this as a cautious move rather than a red flag, especially with 8% growth in global payment volume and signs of healthy core spending. | What matters now is the back half of the year. Visa noted early evidence of consumers front-loading spending ahead of tariff hikes, which could mean softer numbers in Q4. | The company's global footprint and essential nature of its services still make it a strong long-term hold. | Near-term, investors will be focused on cross-border volumes and how macro pressures impact guidance going forward. |
|
| | Edge (Sponsored) | | | The incredible market chaos caused by the current Administration has sent many investors scrambling for solid stock opportunities. | But you don't have to be one of those investors.
Instead, you can leverage the power of your smartphone to get ahead with just one simple step: | Grab our next FREE stock alert, which will deliver the name of a little-known company with exciting short-term growth potential via SMS text. (Don't worry, we've carefully researched it). | Then you'll be "in the know" when the next market breakout happens. | It could even turn out like Alarum Technologies (ALAR). Starting from just $2, this stock recently soared to over $45, which means it gained 2,100%. | Super-windfalls like these are rare, but once you start getting our rapid-fire SMS alerts and analysis, the sky's the limit. | The best part: Our team can deliver all the information you need right to your fingertips… | [Click Here to Discover the Market's Next Hidden Gem]
(By clicking the link above, you agree to receive emails from Krypton Street. You can opt out at any time. - Privacy Policy) |
|
| | Corning | GLW | | Price: $62.61 | Corning delivered a breakout quarter, with revenue up 19% and EPS of $0.60, beating estimates. Its optical communications segment surged 41%, fueled by AI-related infrastructure demand. | Hedge-adjusted revenue came in at $4.05 billion, outpacing forecasts from Mizuho and Bloomberg. | Analysts are now calling for more upside. | Mizuho raised its target to $63, citing above-consensus Q3 guidance. JPMorgan and Citi remain bullish, particularly on the strength of optical enterprise sales, which are up 9% quarter-over-quarter. | The stock has rallied 33% year-to-date and is being discussed as a quiet AI winner. If Apple does launch a foldable iPhone in 2026, Corning is expected to be a primary beneficiary. |
|
| | AstraZeneca | AZN | | Price: $76.60 | AstraZeneca's Q2 results impressed, lifted by strong oncology sales and renewed U.S. demand. CEO Pascal Soriot reaffirmed guidance and pledged a $50 billion investment through 2030 focused on manufacturing and innovation. | With stateside expansion in full swing, the company is building its U.S. presence just as political attention turns toward pharma access and supply chains. | Soriot has positioned AstraZeneca as a global leader in cancer therapy and respiratory medicine. The company's China business remains resilient, and it has avoided major tariff impacts so far. | For long-term investors, the steady results and large-scale vision create a stable base for future growth. | Near-term, continued strength in cancer drug demand and clarity on pricing regulation will shape sentiment. |
|
| | The market is pausing after a record-breaking run, and traders are entering Wednesday focused on the Fed and earnings. | Futures are flat, and expectations for a rate hold sit near 98%. All eyes will be on Powell's post-decision comments, particularly around inflation, tariffs, and the path forward. | Sector leadership may narrow, but analysts are now suggesting that earnings and AI optimism could still drive the S&P 500 higher into year-end. | Capital Economics and others have lifted their targets and noted that multiple sectors, not just tech, are revising earnings upward. This is creating a broader base for selective gains. | In this environment, setups like Amgen's trial momentum or Corning's AI-driven demand can lead to asymmetric returns. Starbucks' execution, Visa's steady core business, and AstraZeneca's global growth plan all add diversity to the mix. | With the Fed, earnings, and geopolitics colliding this week, traders should keep their focus on real signals. That means strong execution, clear catalysts, and resilient demand. |
|
| Best Regards,
—Noah Zelvis
Everyday Alpha |
|
